This site is intended only for US Healthcare Professionals
The current standard of care for people with hemophilia B is lifelong prophylactic treatment with factor IX (FIX) replacement to temporarily replace or supplement low levels of blood-clotting factor.
Prophylactic FIX requires lifelong dedication to a burdensome infusion schedule, often leading to poor adherence because of its impacts on lifestyle and quality of life.
People with hemophilia B who regularly receive FIX replacement can still experience breakthrough bleeds, which can lead to joint damage, pain, and reduced quality of life.
The current standard of care for people with hemophilia B is lifelong prophylactic or preventative treatment with factor IX (FIX) replacement to temporarily replace or supplement low levels of blood-clotting factor.
Prophylactic FIX requires lifelong dedication to a burdensome infusion schedule, often leading to poor adherence because of its impacts on lifestyle and quality of life.
People with hemophilia B who regularly receive FIX replacement can still experience breakthrough bleeds, which can lead to joint damage, pain, and reduced quality of life.
Hemophilia B and its management are associated with significant psychosocial burdens, including anxiety and depression, that impacts both patients and caregivers.
Bleeds from hemophilia B can ultimately lead to permanent physical debilities, acute and/or chronic pain, and severe impacts on a person’s quality of life. Veins may also collapse or harden over time, making ongoing treatment difficult.
Despite meaningful improvements in treatment, there is still a need for new therapeutic advances for people with moderate to severe hemophilia B that provide hope for a long-term benefit and reduce the impact of the disease and its treatment.
Watch Dr. George discuss how gene therapy might help address the impact of hemophilia B on patients.
Sign up for news of advances in gene therapy for hemophilia B.
SIGN UP NOW >